NCT06567314
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Recruiting · Phase 2 · M.D. Anderson Cancer Center · registry updated 2026-06-11
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Inclusion
- Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures.
- Age ≥18 years.
- Has locally advanced surgically non-appropriate (unresectable and/or metastatic) cSCC (Cohort 1)..
- Has metastatic CRPC (Cohort 2):
- Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.
- Documented prostate cancer progression as documented by PSA progression according to PCWG3 criteria.
Exclusion
- Patients who have previously been treated with PD-1/PD-L1 inhibitors and required permanent discontinuation, or systemic immunosuppression due to irAEs.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ivonescimab.
- Pregnant or breastfeeding.
- Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Known history of positive test for human immunodeficiency virus or known acquired immunodeficiency syndrome.
- Known history of acute or chronic hepatitis B virus or hepatitis C virus infection.